FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Bezerra, MP
   Pedrosa, TFB
   Braz, AF
AF Bezerra, Mariana Pires
   Braz Pedrosa, Tiago Farrant
   Braz, Adriana Farrant
TI ENDOCRINOLOGICAL DISORDERS IN CHILDREN WITH CONGENITAL INFECTION OF ZIKA
   VIRUS
SO HORMONE RESEARCH IN PAEDIATRICS
LA English
DT Meeting Abstract
C1 [Bezerra, Mariana Pires; Braz, Adriana Farrant] Campina Grande Fed Univ, Campina Grande, Brazil.
   [Braz Pedrosa, Tiago Farrant; Braz, Adriana Farrant] Campina Grande Med Coll, Campina Grande, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1663-2818
EI 1663-2826
J9 HORM RES PAEDIAT
JI Horm. Res. Paediatr.
PY 2017
VL 88
SU 1
MA P3-502
BP 464
EP 464
PG 1
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA FJ2XT
UT WOS:000412595405082
DA 2020-12-01
ER

PT J
AU Bezerra, AP
   Ramos, AJS
   Braz, AF
AF Bezerra, Arthur Pires
   Santos Ramos, Alberto Jose
   Braz, Adriana Farrant
TI Maturity-Onset Diabetes of the Young (MODY): Tracking and Clinical
   Follow-up
SO HORMONE RESEARCH IN PAEDIATRICS
LA English
DT Meeting Abstract
C1 [Bezerra, Arthur Pires; Santos Ramos, Alberto Jose; Braz, Adriana Farrant] Univ Fed Campina Grande, Campina Grande, Paraiba, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1663-2818
EI 1663-2826
J9 HORM RES PAEDIAT
JI Horm. Res. Paediatr.
PY 2016
VL 86
SU 1
MA P2-P306
BP 245
EP 245
PG 1
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA DX1ZQ
UT WOS:000384166800577
DA 2020-12-01
ER

PT J
AU Braz, AF
   Costalonga, EF
   Trarbach, EB
   Scalco, RC
   Malaquias, AC
   Guerra, G
   Antonini, SRR
   Mendonca, BB
   Arnhold, IJP
   Jorge, AAL
AF Braz, Adriana F.
   Costalonga, Everlayny F.
   Trarbach, Ericka B.
   Scalco, Renata C.
   Malaquias, Alexsandra C.
   Guerra-Junior, Gil
   Antonini, Sonir R. R.
   Mendonca, Berenice B.
   Arnhold, Ivo J. P.
   Jorge, Alexander A. L.
TI Genetic Predictors of Long-Term Response to Growth Hormone (GH) Therapy
   in Children With GH Deficiency and Turner Syndrome: The Influence of a
   SOCS2 Polymorphism
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID RESPONSIVENESS
AB Background: There is great interindividual variability in the response to GH therapy. Ascertaining genetic factors can improve the accuracy of growth response predictions. Suppressor of cytokine signaling (SOCS)-2 is an intracellular negative regulator of GH receptor (GHR) signaling.
   Objective: The objective of the study was to assess the influence of a SOCS2 polymorphism (rs3782415) and its interactive effect with GHR exon 3 and -202 A/C IGFBP3 (rs2854744) polymorphisms on adult height of patients treated with recombinant human GH (rhGH).
   Design and Patients: Genotypes were correlated with adult height data of 65 Turner syndrome (TS) and 47 GH deficiency (GHD) patients treated with rhGH, by multiple linear regressions. Generalized multifactor dimensionality reduction was used to evaluate gene-gene interactions.
   Results: Baseline clinical data were indistinguishable among patients with different genotypes. Adult height SD scores of patients with at least one SOCS2 single-nucleotide polymorphism rs3782415-C were 0.7 higher than those homozygous for the T allele (P < .001). SOCS2 (P < .003), GHR-exon 3 (P = .016) and -202 A/C IGFBP3 (P = .013) polymorphisms, together with clinical factors accounted for 58% of the variability in adult height and 82% of the total height SD score gain. Patients harboring any two negative genotypes in these three different loci (homozygosity for SOCS2 T allele; the GHR exon 3 full-length allele and/or the -202C-IGFBP3 allele) were more likely to achieve an adult height at the lower quartile (odds ratio of 13.3; 95% confidence interval of 3.2-54.2, P = .0001).
   Conclusion: The SOCS2 polymorphism (rs3782415) has an influence on the adult height of children with TS and GHD after long-term rhGH therapy. Polymorphisms located in GHR, IGFBP3, and SOCS2 loci have an influence on the growth outcomes of TS and GHD patients treated with rhGH. The use of these genetic markers could identify among rhGH-treated patients those who are genetically predisposed to have less favorable outcomes.
C1 [Braz, Adriana F.; Trarbach, Ericka B.; Scalco, Renata C.; Malaquias, Alexsandra C.; Jorge, Alexander A. L.] Univ Sao Paulo, Fac Med, Lab Endocrinol Celular & Mol LIM 25, Unidade Endocrinol Genet,Disciplina Endocrinol, BR-01246903 Sao Paulo, Brazil.
   [Braz, Adriana F.; Costalonga, Everlayny F.; Scalco, Renata C.; Malaquias, Alexsandra C.; Mendonca, Berenice B.; Arnhold, Ivo J. P.; Jorge, Alexander A. L.] Univ Sao Paulo, Fac Med, Lab Hormonios & Genet Mol LIM 42, Unidade Endocrinol Desenvolvimento,Disciplina End, BR-05403900 Sao Paulo, Brazil.
   [Guerra-Junior, Gil] Univ Estadual Campinas, Dept Pediat, BR-13083100 Campinas, Brazil.
   [Antonini, Sonir R. R.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Puericultura & Pediat, BR-14040900 Ribeirao Preto, Brazil.
RP Jorge, AAL (corresponding author), Univ Sao Paulo, LIM 25, Fac Med, Ave Dr Arnaldo,455 5 Andar Sala 5340, BR-01246903 Sao Paulo, Brazil.
EM alexj@pq.cnpq.br
RI Scalco, Renata/O-3789-2015; Jorge, Alexander AL/C-7697-2012; ARNHOLD,
   IVO JORGE PRADO/D-2672-2012; Antonini, Sonir RR/J-5264-2015; Malaquias,
   Alexsandra/B-6143-2013; Guerra-Junior, Gil/C-1609-2012; Trarbach,
   Ericka/I-5395-2012; Mendonca, Berenice B/J-6917-2015
OI Scalco, Renata/0000-0002-9523-7697; Jorge, Alexander
   AL/0000-0003-2567-7360; ARNHOLD, IVO JORGE PRADO/0000-0003-1739-1354;
   Guerra-Junior, Gil/0000-0002-2991-7678; Mendonca, Berenice
   B/0000-0003-1762-1084; Antonini, Sonir/0000-0003-4778-8803
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2013/03236-5]; National Council for Scientific and
   Technological DevelopmentNational Council for Scientific and
   Technological Development (CNPq) [307922/2013-8, 301339/2008-9,
   304678/2012-0]
FX This work was supported by Grant 2013/03236-5 from the Sao Paulo
   Research Foundation and Grants 307922/2013-8 ( to I.J.P.A.),
   301339/2008-9 (to B B.M.), and 304678/2012-0 ( to A.A.L.J.) from The
   National Council for Scientific and Technological Development.
CR Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410
   Braz AF, 2012, J CLIN ENDOCR METAB, V97, pE671, DOI 10.1210/jc.2011-2521
   Chan YL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002439
   Clayton P, 2013, EUR J ENDOCRINOL, V169, P277, DOI 10.1530/EJE-13-0069
   Costalonga EF, 2009, J CLIN ENDOCR METAB, V94, P588, DOI 10.1210/jc.2008-1608
   Flores-Morales A, 2006, MOL ENDOCRINOL, V20, P241, DOI 10.1210/me.2005-0170
   Geffner ME, 2007, HORM RES, V68, P51, DOI 10.1159/000110476
   Greenhalgh CJ, 2005, J CLIN INVEST, V115, P397, DOI 10.1172/JCI200522710
   Gudbjartsson DF, 2008, NAT GENET, V40, P609, DOI 10.1038/ng.122
   Lanktree MB, 2011, AM J HUM GENET, V88, P6, DOI 10.1016/j.ajhg.2010.11.007
   Lou XY, 2007, AM J HUM GENET, V80, P1125, DOI 10.1086/518312
   Ranke MB, 2005, J CLIN ENDOCR METAB, V90, P1966, DOI 10.1210/jc.2004-1051
   Ranke MB, 2003, J CLIN ENDOCR METAB, V88, P125, DOI 10.1210/jc.2002-020867
   Ranke MB, 2000, J CLIN ENDOCR METAB, V85, P4212, DOI 10.1210/jc.85.11.4212
   Renehan AG, 2012, AM J EPIDEMIOL, V175, P867, DOI 10.1093/aje/kwr408
   Stevens A, 2014, PHARMACOGENOMICS J, V14, P54, DOI 10.1038/tpj.2013.14
   Wassenaar MJE, 2009, J CLIN ENDOCR METAB, V94, P3721, DOI 10.1210/jc.2009-0425
   Weedon MN, 2008, NAT GENET, V40, P575, DOI 10.1038/ng.121
NR 18
TC 10
Z9 11
U1 0
U2 8
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2014
VL 99
IS 9
BP E1808
EP E1813
DI 10.1210/jc.2014-1744
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AP8PQ
UT WOS:000342341400033
PM 24905066
OA Bronze
DA 2020-12-01
ER

PT J
AU Malaquias, AC
   Scalco, RC
   Fontenele, EGP
   Costalonga, EF
   Baldin, AD
   Braz, AF
   Funari, MFA
   Nishi, MY
   Guerra, G
   Mendonca, BB
   Arnhold, IJP
   Jorge, AAL
AF Malaquias, Alexsandra C.
   Scalco, Renata C.
   Fontenele, Eveline G. P.
   Costalonga, Everlayny F.
   Baldin, Alexandre D.
   Braz, Adriana F.
   Funari, Mariana F. A.
   Nishi, Mirian Y.
   Guerra-Junior, Gil
   Mendonca, Berenice B.
   Arnhold, Ivo J. P.
   Jorge, Alexander A. L.
TI The Sitting Height/Height Ratio for Age in Healthy and Short Individuals
   and Its Potential Role in Selecting Short Children for SHOX Analysis
SO HORMONE RESEARCH IN PAEDIATRICS
LA English
DT Article
DE SHOX gene; Turner syndrome; Idiopathic short stature; Leri-Weill
   dyschondrosteosis
ID LERI-WEILL DYSCHONDROSTEOSIS; IDIOPATHIC SHORT STATURE; HOMEOBOX GENE
   SHOX; TURNER-SYNDROME; DISPROPORTIONATE GROWTH; BODY PROPORTIONS;
   HAPLOINSUFFICIENCY; DEFICIENCY; HEIGHT; PHENOTYPES
AB Aims: To determine the presence of abnormal body proportion, assessed by sitting height/height ratio for age and sex (SH/H SDS) in healthy and short individuals, and to estimate its role in selecting short children for SHOX analysis. Methods: Height, sitting height and weight were evaluated in 1,771 healthy children, 128 children with idiopathic short stature (ISS), 58 individuals with SHOX defects (SHOX-D) and 193 females with Turner syndrome (TS). Results: The frequency of abnormal body proportion, defined as SH/H SDS > 2, in ISS children was 16.4% (95% CI 10-22%), which was higher than in controls (1.4%, 95% CI 0.8-1.9%, p < 0.001). The SHOX gene was evaluated in all disproportionate ISS children and defects in this gene were observed in 19%. Among patients with SHOX-D, 88% of children (95% CI 75-100%) and 96% of adults had body disproportion. In contrast, SH/H SDS > 2 were less common in children (48%, 95% CI 37-59%) and in adults (28%, 95% CI 20-36%) with TS. Conclusion: Abnormal body proportions were observed in almost all individuals with SHOX-D, 50% of females with TS and 16% of children considered ISS. Defects in SHOX gene were identified in 19% of ISS children with SH/H SDS > 2, suggesting that SH/H SDS is a useful tool to select children for undergoing SHOX molecular studies. (C) 2013 S. Karger AG, Basel
C1 [Malaquias, Alexsandra C.; Scalco, Renata C.; Braz, Adriana F.; Jorge, Alexander A. L.] Univ Sao Paulo, Fac Med, Disciplina Endocrinol, Unidade Endocrinol Genet,LIM 25, Sao Paulo, Brazil.
   [Malaquias, Alexsandra C.; Scalco, Renata C.; Braz, Adriana F.; Funari, Mariana F. A.; Nishi, Mirian Y.; Mendonca, Berenice B.; Arnhold, Ivo J. P.; Jorge, Alexander A. L.] Univ Sao Paulo, Fac Med, Hosp Clin,Lab Hormonios & Genet Mol, Unidade Endocrinol Desenvolvimento,LIM 42, Sao Paulo, Brazil.
   [Fontenele, Eveline G. P.] Univ Fed Ceara, Fac Med, Unidade Farmacol Clin, Serv Endocrinol Diabet,HUWC UFC, Fortaleza, Ceara, Brazil.
   [Costalonga, Everlayny F.] Univ Vila Velha, Programa Pos Grad Ciencias Farmaceut, Vila Velha, Brazil.
   [Baldin, Alexandre D.; Guerra-Junior, Gil] Univ Estadual Campinas, UNICAMP, Fac Ciencias Med, Lab Crescimento & Composicao Corporal,Ctr Invest, Campinas, Brazil.
RP Jorge, AAL (corresponding author), USP LIM 25, Fac Med, Ave Dr Arnaldo,455 5 Andar Sala 5340, BR-01246903 Sao Paulo, Brazil.
EM alexj@usp.br
RI Fontenele, Eveline Gadelha Pereira/D-4728-2012; Scalco,
   Renata/O-3789-2015; ARNHOLD, IVO JORGE PRADO/D-2672-2012; Jorge,
   Alexander AL/C-7697-2012; Guerra-Junior, Gil/C-1609-2012; Nishi, Mirian
   Y/C-5144-2012; Malaquias, Alexsandra/B-6143-2013; Mendonca, Berenice
   B/J-6917-2015
OI Fontenele, Eveline Gadelha Pereira/0000-0002-3220-1320; Scalco,
   Renata/0000-0002-9523-7697; ARNHOLD, IVO JORGE
   PRADO/0000-0003-1739-1354; Jorge, Alexander AL/0000-0003-2567-7360;
   Guerra-Junior, Gil/0000-0002-2991-7678; Nishi, Mirian
   Y/0000-0001-6603-3188; Mendonca, Berenice B/0000-0003-1762-1084
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2008/50184-2,
   2013/03236-5, 2007/59555-0]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPqNational Council for Scientific and
   Technological Development (CNPq) [301339/2008-9, 300982/2009-7,
   304678/2012-0]
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo - FAPESP (2008/50184-2, 2013/03236-5 and
   2007/59555-0 to A. C. M.) and from Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq (301339/2008-9 to B. B. M.;
   300982/2009-7 to I.J.P.A. and 304678/2012-0 to A.A.L.J.).
CR Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410
   Baldin Alexandre D., 2005, Arq Bras Endocrinol Metab, V49, P529, DOI 10.1590/S0004-27302005000400010
   Belin V, 1998, NAT GENET, V19, P67, DOI 10.1038/ng0198-67
   Binder G, 2003, J CLIN ENDOCR METAB, V88, P4891, DOI 10.1210/jc.2003-030136
   Blum WF, 2009, HORM RES, V71, P167, DOI 10.1159/000197874
   Clement-Jones M, 2000, HUM MOL GENET, V9, P695, DOI 10.1093/hmg/9.5.695
   Ellison JW, 1997, HUM MOL GENET, V6, P1341, DOI 10.1093/hmg/6.8.1341
   Fredriks AM, 2005, ARCH DIS CHILD, V90, P807, DOI 10.1136/adc.2004.050799
   Fukami M, 2004, ENDOCR J, V51, P197, DOI 10.1507/endocrj.51.197
   Funari MFA, 2010, EUR J MED GENET, V53, P234, DOI 10.1016/j.ejmg.2010.06.001
   Gravholt CH, 1997, AM J MED GENET, V72, P403
   Hirschfeldova K, 2012, GENE, V491, P123, DOI 10.1016/j.gene.2011.10.011
   Jorge AA, 2007, J MED GENET, V44, pe91
   Jorge Alexander A L, 2007, J Med Genet, V44, pe91
   Jorge Alexander A L, 2010, Pediatr Endocrinol Rev, V8, P79
   Jorge AAL, 2007, CLIN ENDOCRINOL, V66, P130, DOI 10.1111/j.1365-2265.2006.02698.x
   Kant SG, 2013, PEERJ, V1, DOI 10.7717/peerj.35
   Kosho T, 1999, J CLIN ENDOCR METAB, V84, P4613, DOI 10.1210/jc.84.12.4613
   Kuczmarski R J, 2000, Adv Data, P1
   NEUFELD ND, 1978, AM J DIS CHILD, V132, P296, DOI 10.1001/archpedi.1978.02120280080018
   Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54
   Rappold GA, 2002, J CLIN ENDOCR METAB, V87, P1402, DOI 10.1210/jc.87.3.1402
   Rappold G, 2007, J MED GENET, V44, P306, DOI 10.1136/jmg.2006.046581
   RONGENWESTERLAKEN C, 1993, EUR J PEDIATR, V152, P813, DOI 10.1007/BF02073377
   Ross JL, 2005, J PEDIATR-US, V147, P499, DOI 10.1016/j.jpeds.2005.04.069
   Ross JL, 2001, J CLIN ENDOCR METAB, V86, P5674, DOI 10.1210/jc.86.12.5674
   Silva DAS, 2010, J PEDIAT-BRAZIL, V86, P115, DOI [10.2223/JPED.1975, 10.1590/S0021-75572010000200006]
   Scalco RC, 2010, J CLIN ENDOCR METAB, V95, P328, DOI 10.1210/jc.2009-1577
   Shears DJ, 1998, NAT GENET, V19, P70, DOI 10.1038/ng0198-70
NR 29
TC 35
Z9 36
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1663-2818
EI 1663-2826
J9 HORM RES PAEDIAT
JI Horm. Res. Paediatr.
PY 2013
VL 80
IS 6
BP 449
EP 456
DI 10.1159/000355411
PG 8
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA 295RN
UT WOS:000330133300011
PM 24296787
DA 2020-12-01
ER

PT J
AU Costalonga, EF
   Antonini, SRR
   Guerra, G
   Coletta, RRD
   Franca, MM
   Braz, AF
   Mendonca, BB
   Arnhold, IJP
   Jorge, AAL
AF Costalonga, E. F.
   Antonini, S. R. R.
   Guerra-Junior, G.
   Coletta, R. R. D.
   Franca, M. M.
   Braz, A. F.
   Mendonca, B. B.
   Arnhold, I. J. P.
   Jorge, A. A. L.
TI Growth hormone pharmacogenetics: the interactive effect of a
   microsatellite in the IGF1 promoter region with the GHR-exon 3 and-202
   A/C IGFBP3 variants on treatment outcomes of children with severe GH
   deficiency
SO PHARMACOGENOMICS JOURNAL
LA English
DT Article
DE dwarfism; growth hormone/deficiency; growth hormone/therapeutic use;
   pharmacogenetics; insulin-like growth factor type 1; genetic variation
ID FACTOR-BINDING PROTEIN-3; FOR-GESTATIONAL-AGE; ADULT HEIGHT; FACTOR-I;
   PREPUBERTAL CHILDREN; FINAL HEIGHT; GENE; POLYMORPHISM; RECEPTOR;
   PREDICTION
AB Insulin-like growth factor type 1 (IGF1) is a mediator of growth hormone (GH) action, and therefore, IGF1 is a candidate gene for recombinant human GH (rhGH) pharmacogenetics. Lower serum IGF1 levels were found in adults homozygous for 19 cytosine-adenosine (CA) repeats in the IGF1 promoter. The aim of this study was to evaluate the influence of (CA)n IGF1 polymorphism, alone or in combination with GH receptor (GHR)-exon 3 and -202 A/C insulin-like growth factor binding protein-3 (IGFBP3) polymorphisms, on the growth response to rhGH therapy in GH-deficient (GHD) patients. Eighty-four severe GHD patients were genotyped for (CA) n IGF1, -202 A/C IGFBP3 and GHR-exon 3 polymorphisms. Multiple linear regressions were performed to estimate the effect of each genotype, after adjustment for other influential factors. We assessed the influence of genotypes on the first year growth velocity (1st y GV) (n = 84) and adult height standard deviation score (SDS) adjusted for target-height SDS (AH-TH SDS) after rhGH therapy (n = 37). Homozygosity for the IGF1 19CA repeat allele was negatively correlated with 1st y GV (P = 0.03) and AH-TH SDS (P = 0.002) in multiple linear regression analysis. In conjunction with clinical factors, IGF1 and IGFBP3 genotypes explain 29% of the 1st y GV variability, whereas IGF1 and GHR polymorphisms explain 59% of final height-target-height SDS variability. We conclude that homozygosity for IGF1 (CA) 19 allele is associated with less favorable short-and long-term growth outcomes after rhGH treatment in patients with severe GHD. Furthermore, this polymorphism exhibits a non-additive interaction with -202 A/C IGFBP3 genotype on the 1st y GV and with GHR-exon 3 genotype on adult height. The Pharmacogenomics Journal (2012) 12, 439-445; doi:10.1038/tpj.2011.13; published online 5 April 2011
C1 [Costalonga, E. F.; Coletta, R. R. D.; Franca, M. M.; Braz, A. F.; Mendonca, B. B.; Arnhold, I. J. P.; Jorge, A. A. L.] Univ Sao Paulo, Fac Med, Disciplina Endocrinol,Hosp Clin, Unidade Endocrinol Desenvolvimento,Lab Hormonios, BR-01246903 Sao Paulo, Brazil.
   [Antonini, S. R. R.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-01246903 Sao Paulo, Brazil.
   [Guerra-Junior, G.] Univ Estadual Campinas, Fac Med, Dept Pediat, Sao Paulo, Brazil.
   [Jorge, A. A. L.] Univ Sao Paulo FMUSP, Fac Med, Disciplina Endocrinol, Unidade Endocrinol Genet LIM Hosp Clin 25, Sao Paulo, Brazil.
RP Costalonga, EF (corresponding author), Univ Sao Paulo, Fac Med, Disciplina Endocrinol,Hosp Clin, Unidade Endocrinol Desenvolvimento,Lab Hormonios, Ave Dr Arnaldo 455,5 Andar,Sala 5340, BR-01246903 Sao Paulo, Brazil.
EM laynyfiorot@hotmail.com; alexj@usp.br
RI ARNHOLD, IVO JORGE PRADO/D-2672-2012; Jorge, Alexander AL/C-7697-2012;
   Guerra-Junior, Gil/C-1609-2012; Mendonca, Berenice B/J-6917-2015;
   Antonini, Sonir RR/J-5264-2015
OI ARNHOLD, IVO JORGE PRADO/0000-0003-1739-1354; Jorge, Alexander
   AL/0000-0003-2567-7360; Guerra-Junior, Gil/0000-0002-2991-7678;
   Mendonca, Berenice B/0000-0003-1762-1084; Antonini,
   Sonir/0000-0003-4778-8803
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [05/04726-0,
   06/55763-5]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPqNational Council for Scientific and Technological
   Development (CNPq) [301339/2008-9, 300982/2009-7, 475870/2009-3,
   301477/2009-4]
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo-FAPESP (05/04726-0 and 06/55763-5 to EFC) and from
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq
   (301339/2008-9 to BBM; 300982/2009-7 to IJPA; 475870/2009-3 and
   301477/2009-4 to AALJ).
CR Arends N, 2002, J CLIN ENDOCR METAB, V87, P2720, DOI 10.1210/jc.87.6.2720
   Carel JC, 2002, BMJ-BRIT MED J, V325, P70, DOI 10.1136/bmj.325.7355.70
   Clemmons DR, 2001, HORM RES, V55, P73, DOI 10.1159/000063480
   Cordell HJ, 2009, NAT REV GENET, V10, P392, DOI 10.1038/nrg2579
   Costalonga EF, 2009, J CLIN ENDOCR METAB, V94, P588, DOI 10.1210/jc.2008-1608
   de Ridder MAJ, 2007, J CLIN ENDOCR METAB, V92, P925, DOI 10.1210/jc.2006-1259
   Ester WA, 2008, BEST PRACT RES CL EN, V22, P415, DOI 10.1016/j.beem.2008.03.001
   Frayling TM, 2002, DIABETES, V51, P2313, DOI 10.2337/diabetes.51.7.2313
   FRISCH H, 1995, HORM RES, V43, P132, DOI 10.1159/000184258
   Geffner ME, 2007, HORM RES, V68, P51, DOI 10.1159/000110476
   Greulich WW, 1959, RADIOGRAPHIC ATLAS S
   Harrela M, 1996, J CLIN INVEST, V98, P2612, DOI 10.1172/JCI119081
   Israel E, 2000, J CLIN ENDOCR METAB, V85, P3990
   Jernstrom H, 2001, CANCER EPIDEM BIOMAR, V10, P377
   Jorge AAL, 2006, J CLIN ENDOCR METAB, V91, P1076, DOI 10.1210/jc.2005-2005
   Jorge AAL, 2009, HORM RES, V71, P55, DOI 10.1159/000192438
   Kristrom B, 2002, HORM RES, V57, P66, DOI 10.1159/000058104
   Lettre G, 2007, HUM GENET, V122, P129, DOI 10.1007/s00439-007-0385-4
   Li HJ, 2005, J CLIN ENDOCR METAB, V90, P3659, DOI 10.1210/jc.2004-2079
   Li WT, 2000, HUM HERED, V50, P334, DOI 10.1159/000022939
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Rocha MGM, 2008, J PEDIATR ENDOCR MET, V21, P673
   Ohlsson C, 2009, ENDOCR REV, V30, P494, DOI 10.1210/er.2009-0010
   Pantel J, 2000, J BIOL CHEM, V275, P18664, DOI 10.1074/jbc.M001615200
   Ranke MB, 1999, J CLIN ENDOCR METAB, V84, P1174, DOI 10.1210/jc.84.4.1174
   Rietveld I, 2003, EUR J ENDOCRINOL, V148, P171, DOI 10.1530/eje.0.1480171
   Rosen CJ, 1998, J CLIN ENDOCR METAB, V83, P2286, DOI 10.1210/jc.83.7.2286
   Silva EGP, 2003, HORM RES, V59, P229, DOI 10.1159/000070222
   Stochholm K, 2006, EUR J ENDOCRINOL, V155, P61, DOI 10.1530/eje.1.02191
   TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613
   Vaessen N, 2001, DIABETES, V50, P637, DOI 10.2337/diabetes.50.3.637
   van der Kaay DCM, 2009, GROWTH HORM IGF RES, V19, P198, DOI 10.1016/j.ghir.2008.08.010
   Wassenaar MJE, 2009, J CLIN ENDOCR METAB, V94, P3721, DOI 10.1210/jc.2009-0425
   WEBER JL, 1989, AM J HUM GENET, V44, P388
   Wit JM, 2007, HORM RES, V68, P244, DOI 10.1159/000101428
   Wit JM, 1996, PEDIATR RES, V39, P295, DOI 10.1203/00006450-199602000-00018
NR 36
TC 15
Z9 15
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1470-269X
EI 1473-1150
J9 PHARMACOGENOMICS J
JI Pharmacogenomics J.
PD OCT
PY 2012
VL 12
IS 5
BP 439
EP 445
DI 10.1038/tpj.2011.13
PG 7
WC Genetics & Heredity; Pharmacology & Pharmacy
SC Genetics & Heredity; Pharmacology & Pharmacy
GA 012CM
UT WOS:000309213000012
PM 21468024
OA Bronze
DA 2020-12-01
ER

PT J
AU Braz, AF
   Costalonga, EF
   Montenegro, LR
   Trarbach, EB
   Antonini, SRR
   Malaquias, AC
   Ramos, ES
   Mendonca, BB
   Arnhold, IJP
   Jorge, AAL
AF Braz, Adriana F.
   Costalonga, Everlayny F.
   Montenegro, Luciana R.
   Trarbach, Ericka B.
   Antonini, Sonir R. R.
   Malaquias, Alexsandra C.
   Ramos, Ester S.
   Mendonca, Berenice B.
   Arnhold, Ivo J. P.
   Jorge, Alexander A. L.
TI The Interactive Effect of GHR-Exon 3 and -202 A/C IGFBP3 Polymorphisms
   on rhGH Responsiveness and Treatment Outcomes in Patients with Turner
   Syndrome
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID FACTOR-BINDING PROTEIN-3; GROWTH-HORMONE TREATMENT; FOR-GESTATIONAL-AGE;
   RECEPTOR POLYMORPHISM; PROMOTER POLYMORPHISM; SERUM-LEVELS; GH-RECEPTOR;
   CHILDREN; HEIGHT; GIRLS
AB Context: There is great interindividual variability in the response to recombinant human (rh) GH therapy in patients with Turner syndrome (TS). Ascertaining genetic factors can improve the accuracy of growth response predictions.
   Objective: The objective of the study was to assess the individual and combined influence of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on the short-and long-term outcomes of rhGH therapy in patients with TS.
   Design and Patients: GHR-exon 3 and -202 A/C IGFBP3 genotyping (rs2854744) was correlated with height data of 112 patients with TS who remained prepubertal during the first year of rhGH therapy and 65 patients who reached adult height after 5 +/- 2.5 yr of rhGH treatment.
   Main Outcome Measures: First-year growth velocity and adult height were measured.
   Results: Patients carrying at least one GHR-d3 or -202 A-IGFBP3 allele presented higher mean first-year growth velocity and achieved taller adult heights than those homozygous for GHR-fl or -202 C-IGFBP3 alleles, respectively. The combined analysis of GHR-exon 3 and -202 A/C IGFBP3 genotypes showed a clear nonadditive epistatic influence on adult height of patients with TS treated with rhGH (GHR-exon 3 alone, R-2 = 0.27; -202 A/C IGFBP3, R-2 = 0.24; the combined genotypes, R-2 = 0.37 at multiple linear regression). Together with clinical factors, these genotypes accounted for 61% of the variability in adult height of patients with TS after rhGH therapy.
   Conclusion: Homozygosity for the GHR-exon3 full-length allele and/or the -202C-IGFBP3 allele are associated with less favorable short-and long-term growth outcomes after rhGH treatment in patients with TS. (J Clin Endocrinol Metab 97: E671-E677, 2012)
C1 [Braz, Adriana F.; Costalonga, Everlayny F.; Montenegro, Luciana R.; Malaquias, Alexsandra C.; Mendonca, Berenice B.; Arnhold, Ivo J. P.] Univ Sao Paulo, Fac Med, Disciplina Endocrinol,Hosp Clin, Unidade Endocrinol Desenvolvimento,Lab Hormonios, BR-05403900 Sao Paulo, Brazil.
   [Antonini, Sonir R. R.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-05508 Sao Paulo, Brazil.
   [Ramos, Ester S.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Genet, BR-14040900 Sao Paulo, Brazil.
   [Braz, Adriana F.; Trarbach, Ericka B.; Malaquias, Alexsandra C.; Jorge, Alexander A. L.] Univ Sao Paulo, Fac Med, Disciplina Endocrinol,Hosp Clin, Unidade Endocrinol Genet,Lab Endocrinol Celular &, BR-01246903 Sao Paulo, Brazil.
RP Jorge, AAL (corresponding author), Univ Sao Paulo, Fac Med, LIM 25,Ave Dr Arnaldo 455,5 Degree Andar,Sala 534, BR-01246903 Sao Paulo, Brazil.
EM alexj@usp.br
RI ARNHOLD, IVO JORGE PRADO/D-2672-2012; Ramos, Ester/K-4045-2012;
   Trarbach, Ericka/I-5395-2012; Jorge, Alexander AL/C-7697-2012; Mendonca,
   Berenice B/J-6917-2015; Antonini, Sonir RR/J-5264-2015; Ramos,
   Ester/E-3200-2019; Malaquias, Alexsandra/B-6143-2013
OI ARNHOLD, IVO JORGE PRADO/0000-0003-1739-1354; Jorge, Alexander
   AL/0000-0003-2567-7360; Mendonca, Berenice B/0000-0003-1762-1084; Ramos,
   Ester/0000-0001-7253-2143; Antonini, Sonir/0000-0003-4778-8803
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [05/04726-0, 05/50144-2];
   Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
   [301339/2008-9, 300938/06-3, 475870/2009-3, 301477/2009-4]
FX This work was supported by Grants 05/04726-0 and 05/50144-2 from the
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (to L. R. M.) and
   Grants 301339/2008-9 (to B. B. M.), 300938/06-3 (to I.J.P.A.), and
   475870/2009-3 and 301477/2009-4 (to A.A.L.J.) from the Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico.
CR Alvarez-Nava F, 2010, J PEDIATR ENDOCR MET, V23, P773, DOI 10.1515/jpem.2010.127
   Audi L, 2006, J CLIN ENDOCR METAB, V91, P5038, DOI 10.1210/jc.2006-0828
   Bannink EMN, 2006, CLIN ENDOCRINOL, V65, P310, DOI 10.1111/j.1365-2265.2006.02594.x
   Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967
   Binder G, 2006, J CLIN ENDOCR METAB, V91, P659, DOI 10.1210/jc.2005-1581
   Binder G, 2008, CLIN ENDOCRINOL, V68, P567, DOI 10.1111/j.1365-2265.2007.03090.x
   Bondy CA, 2007, J CLIN ENDOCR METAB, V92, P10, DOI 10.1210/jc.2006-1374
   Clement-Jones M, 2000, HUM MOL GENET, V9, P695, DOI 10.1093/hmg/9.5.695
   Costalonga EF, 2012, PHARMACOGENOMICS J, V12, P439, DOI 10.1038/tpj.2011.13
   Costalonga EF, 2009, J CLIN ENDOCR METAB, V94, P588, DOI 10.1210/jc.2008-1608
   Deal C, 2001, J CLIN ENDOCR METAB, V86, P1274, DOI 10.1210/jc.86.3.1274
   Dos Santos C, 2004, NAT GENET, V36, P720, DOI 10.1038/ng1379
   Geffner ME, 2007, HORM RES, V68, P51, DOI 10.1159/000110476
   Greulich WW, 1959, RADIOGRAPHIC ATLAS S
   Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J
   Jogie-Brahim S, 2009, ENDOCR REV, V30, P417, DOI 10.1210/er.2008-0028
   Jorge AAL, 2009, HORM RES, V71, P55, DOI 10.1159/000192438
   Ko JM, 2010, CLIN ENDOCRINOL, V72, P196, DOI 10.1111/j.1365-2265.2009.03681.x
   Kuczmarski R J, 2000, Adv Data, P1
   Meyer S, 2009, PHARMACOGENOMICS, V10, P1599, DOI 10.2217/PGS.09.91
   Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019
   Mullis PE, 2011, BEST PRACT RES CL EN, V25, P25, DOI 10.1016/j.beem.2010.06.006
   Pantel J, 2000, J BIOL CHEM, V275, P18664, DOI 10.1074/jbc.M001615200
   Ranke MB, 2007, PEDIATR RES, V61, P105, DOI 10.1203/01.pdr.0000250039.42000.c9
   Ross JL, 2011, NEW ENGL J MED, V364, P1230, DOI 10.1056/NEJMoa1005669
   Stephure DK, 2005, J CLIN ENDOCR METAB, V90, P3360, DOI 10.1210/jc.2004-2187
   TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454
   van der Kaay DCM, 2009, GROWTH HORM IGF RES, V19, P198, DOI 10.1016/j.ghir.2008.08.010
   van Pareren YK, 2003, J CLIN ENDOCR METAB, V88, P1119, DOI 10.1210/jc.2002-021171
   Wassenaar MJE, 2009, J CLIN ENDOCR METAB, V94, P3721, DOI 10.1210/jc.2009-0425
NR 30
TC 11
Z9 13
U1 0
U2 6
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2012
VL 97
IS 4
BP E671
EP E677
DI 10.1210/jc.2011-2521
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 925US
UT WOS:000302787800024
PM 22278433
OA Bronze
DA 2020-12-01
ER

PT J
AU Boy, R
   Krug, B
   Picon, C
   Santana-Da-Silva, L
   Steiner, C
   Acosta, A
   Ribeiro, E
   Marcial, F
   Braz, A
   Leivas, P
   Braz, M
   Schwartz, I
AF Boy, R.
   Krug, B.
   Picon, C.
   Santana-da-Silva, L.
   Steiner, C.
   Acosta, A.
   Ribeiro, E.
   Marcial, F.
   Braz, A.
   Leivas, P.
   Braz, M.
   Schwartz, I
TI LITIGATION IN HEALTH: THE EXAMPLE OF LARONIDASE FOR THE TREATMENT OF
   MPSI IN BRAZIL
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Meeting Abstract
C1 [Boy, R.] Univ Estado Rio De Janeiro, Ped Dept, Rio De Janeiro, Brazil.
   [Krug, B.; Schwartz, I] HCPA, Med Genet Serv, Porto Alegre, RS, Brazil.
   [Picon, C.] Univ Fed Rio Grande do Sul, HCPA, Porto Alegre, RS, Brazil.
   [Santana-da-Silva, L.] UFPA, Inst Biol Sci, Para, Brazil.
   [Steiner, C.] Univ Estadual Campinas, Med Gen Dept, Campinas, SP, Brazil.
   [Acosta, A.] Univ Fed Bahia, Ped Dep, Salvador, BA, Brazil.
   [Ribeiro, E.] Albert Sabin Child Hosp, Fortaleza, Ceara, Brazil.
   [Braz, A.; Braz, M.] Fiocruz MS, DepSocSci, BR-21045900 Rio De Janeiro, Brazil.
   [Leivas, P.] Sch Law, Porto Alegre, RS, Brazil.
RI Schwartz, Ida/M-1422-2015
OI Schwartz, Ida/0000-0002-7933-6687
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD AUG
PY 2010
VL 33
SU 1
BP S184
EP S184
PG 1
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 648ZT
UT WOS:000281735000603
DA 2020-12-01
ER

EF